Advertisement
Home 2017 July

Monthly Archives: July 2017

Reducing hospital readmission rates for acute myocardial infarction

Reducing Hospital Readmissions Doesn’t Up Mortality Rates

0
ACA guidelines may mean better follow-up after discharge, researchers suggest
Postoperative pain is frequently underrated when assessed by nursing staff on wards

Post-Op Pain May Often Be Underrated by Inpatient Staff

0
Cross sectional data comparison of pain assessment showed large gap of underrated pain
In a report published online July 16 in the Journal of Clinical Pharmacy and Therapeutics

Survival Feasible Post Acute Liver Failure Secondary to Amiodarone

0
Case report describes survival of 79-year-old woman treated with IV amiodarone for atrial flutter
Adherence to distress screening protocols by cancer programs is associated with lower rates of medical service utilization

Distress Screening Tied to Fewer ER Visits for Cancer Patients

0
Lower risk ratios for ER use and hospitalization when cancer program adherence documented
A rare case of secondary syphilis which primarily presented with multiple nodules on the scalp has been detailed in a case report published online July 17 in the Journal of Dermatology.

Rare Skin Manifestations Can Indicate Secondary Syphilis

0
Case report describes 51-year-old man who primarily presented with multiple nodules on his scalp
For pediatric and adolescent oncology patients

Single-Dose PCV13 Immunogenic, Safe in Pediatric Oncology

0
After vaccination, ≥70 percent had protective antibody titers for S. pneumoniae serotypes
For patients with type 2 diabetes mellitus

Electronic Messaging Intervention Cuts Cardiovascular Risk in T2DM

0
Intervention effective for reducing cardiovascular risk in patients with type 2 diabetes
Patients with advanced Alzheimer's can relearn some basic skills when they receive special training along with medication

AAIC: Rx + Training Shows Benefit in Advanced Alzheimer’s

0
Skills lost, such as dressing or bathing, can potentially be relearned, small study suggests
Nerlynx (neratinib) has been approved by the U.S. Food and Drug Administration to help prevent human epidermal growth factor receptor type 2-positive breast cancer from returning.

FDA Approves Nerlynx to Help Prevent HER2+ Breast CA Return

0
Drug is a kinase inhibitor that works by blocking several enzymes that promote cell growth
A practice guidance statement

Guidelines Updated for Diagnosis, Management of NAFLD

0
Liver biopsy is best for those who would benefit from diagnostic, therapeutic guidance